Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 72.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 18,054 shares of the pharmaceutical company’s stock after acquiring an additional 7,570 shares during the period. Landscape Capital Management L.L.C.’s holdings in Vertex Pharmaceuticals were worth $8,185,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Cladis Investment Advisory LLC acquired a new stake in Vertex Pharmaceuticals during the fourth quarter valued at $246,000. Cornerstone Financial Management LLC acquired a new stake in Vertex Pharmaceuticals during the fourth quarter valued at $83,000. Dymon Asia Capital Singapore PTE. LTD. acquired a new stake in Vertex Pharmaceuticals during the fourth quarter valued at $1,904,000. Arax Advisory Partners grew its position in Vertex Pharmaceuticals by 20.6% during the fourth quarter. Arax Advisory Partners now owns 1,976 shares of the pharmaceutical company’s stock valued at $896,000 after buying an additional 337 shares during the period. Finally, Bard Associates Inc. acquired a new stake in Vertex Pharmaceuticals during the fourth quarter valued at $159,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

VRTX has been the topic of several research analyst reports. Barclays lifted their target price on shares of Vertex Pharmaceuticals from $607.00 to $615.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Truist Financial initiated coverage on shares of Vertex Pharmaceuticals in a research report on Wednesday, May 27th. They issued a “buy” rating and a $542.00 target price on the stock. Oppenheimer lifted their target price on shares of Vertex Pharmaceuticals from $540.00 to $600.00 and gave the company an “outperform” rating in a research report on Tuesday, March 10th. Weiss Ratings upgraded shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, May 18th. Finally, Wall Street Zen lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 30th. Twenty-two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $555.91.

Insider Buying and Selling

In related news, CMO Carmen Bozic sold 6,988 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $450.00, for a total transaction of $3,144,600.00. Following the transaction, the chief marketing officer directly owned 26,088 shares in the company, valued at approximately $11,739,600. The trade was a 21.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sangeeta N. Bhatia sold 318 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $423.73, for a total transaction of $134,746.14. Following the transaction, the director owned 4,924 shares in the company, valued at $2,086,446.52. The trade was a 6.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 11,133 shares of company stock worth $4,973,106. 0.20% of the stock is owned by insiders.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex received bullish attention from market commentary highlighting that Wall Street remains interested in the stock despite a bearish “death cross” technical setup, suggesting investors are focusing more on the company’s fundamentals than the chart pattern. Article Title
• Positive Sentiment: The company announced new CASGEVY data at the European Hematology Association Congress, including the first European presentation of results in children ages 5–11 and additional global regulatory submissions, which could support longer-term growth for the gene-editing therapy. Article Title
• Positive Sentiment: Analysts and media coverage have been broadly upbeat on Vertex, including pieces describing it as a favored healthcare stock and a stock some investors view as attractive to buy now, reinforcing confidence in the name. Article Title
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate for Vertex to $19.24 from $19.36, a small revision that may not materially change the long-term outlook but is a minor headwind for sentiment. Article Title
• Negative Sentiment: The stock has also experienced a recent pullback in some sessions, reflecting normal volatility and some profit-taking even as the broader narrative remains constructive. Article Title

Vertex Pharmaceuticals Stock Down 0.0%

Shares of NASDAQ VRTX opened at $444.92 on Friday. The company’s 50-day simple moving average is $437.14 and its 200-day simple moving average is $452.33. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $507.92. The firm has a market cap of $112.92 billion, a price-to-earnings ratio of 26.39, a price-to-earnings-growth ratio of 1.90 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share for the quarter, topping analysts’ consensus estimates of $4.24 by $0.23. The firm had revenue of $2.99 billion for the quarter, compared to analyst estimates of $2.99 billion. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. Vertex Pharmaceuticals’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the business posted $4.06 earnings per share. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 17.02 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.